Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | WRN | Q14191 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16746890 | 0.83 | ALOX5 (0.46) | GAAALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL27716080 | 0.82 | WRN (0.42) | GAAMAPK1ALDH1A1KMT2AMEN1 | |
| SCHEMBL26066484 | 0.82 | ALDH1A1 (0.36) | GAAMAPK1ALDH1A1KMT2AMEN1 | |
| SCHEMBL25358293 | 0.82 | ALDH1A1 (0.45) | GAAMAPK1ALDH1A1KMT2AMEN1 | |
| SCHEMBL29045259 | 0.80 | GABBR2 (0.43) | GAAMAPK1ALDH1A1KMT2AMEN1 | |
| SCHEMBL29045244 | 0.80 | TSHR (0.38) | GAAALDH1A1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL29045332 | 0.79 | HPGD (0.42) | GAAALDH1A1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL14507024 | 0.72 | WRN (0.42) | GAAMAPK1ALDH1A1KMT2AMEN1 | |
| SCHEMBL20543810 | 0.72 | MAPK1 (0.42) | GAAMAPK1ALDH1A1KMT2AMEN1 | |
| SCHEMBL2737323 | 0.72 | WRN (0.41) | GAAMAPK1ALDH1A1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4476228-A1 | 4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2023154309-A1 | 4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154309-A1 | 4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| CN-116547287-A | Inhibitors of APOL1 and methods of use thereof | 弗特克斯药品有限公司 | 2023-08-04 | — | — | CN | disclosed |
| US-20220106327-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106327-A1 | INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PNLIP, APOB | GAA 1566/4885MAPK1 1799/4885ALDH1A1 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.